

CORRECTION

Open Access



# Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Chris Ebong<sup>1\*</sup>, Asadu Sserwanga<sup>1</sup>, Jane Frances Namuganga<sup>1</sup>, James Kapisi<sup>1</sup>, Arthur Mpimbaza<sup>1</sup>, Samuel Gonahasa<sup>1</sup>, Victor Asua<sup>1</sup>, Sam Gudoi<sup>2</sup>, Ruth Kigozi<sup>2</sup>, James Tibenderana<sup>2</sup>, John Bosco Bwanika<sup>2</sup>, Agaba Bosco<sup>3</sup>, Denis Rubahika<sup>3</sup>, Daniel Kyabayinze<sup>3</sup>, Jimmy Opigo<sup>3</sup>, Damian Rutazana<sup>3</sup>, Gloria Sebikaari<sup>4</sup>, Kassahun Belay<sup>4</sup>, Mame Niang<sup>4</sup>, Eric S. Halsey<sup>5</sup>, Leah F. Moriarty<sup>5</sup>, Naomi W. Lucchi<sup>5</sup>, Samaly S. Svigel Souza<sup>5</sup>, Sam L. Nsobya<sup>1,6</sup>, Moses R. Kanya<sup>1,6</sup> and Adoke Yeka<sup>1,6</sup>

## Correction to: *Malaria Journal* (2021) 20:484

<https://doi.org/10.1186/s12936-021-04021-5>

Following publication of the original article [1], it was brought to the publisher's attention that incorrect details had been provided in the trial registration information of the article.

### Where it should read:

Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (<https://pactr.samrc.ac.za/>) with study Trial No. PACTR201811640750761.

### It said:

Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761.

The original article has been updated accordingly.

### Author details

<sup>1</sup>Infectious Diseases Research Collaboration, Kampala, Uganda. <sup>2</sup>USAID's Malaria Action Program for Districts, Kampala, Uganda. <sup>3</sup>National Malaria Control Division, Ministry of Health Uganda, Kampala, Uganda. <sup>4</sup>U.S. President's Malaria Initiative, Kampala, Uganda. <sup>5</sup>Malaria Branch, Centers for Disease Control and Prevention & President's Malaria Initiative, Atlanta, GA, USA. <sup>6</sup>Makerere University College of Health Sciences, Kampala, Uganda.

The original article can be found online at <https://doi.org/10.1186/s12936-021-04021-5>.

Published online: 07 February 2022

\*Correspondence: [echochris2@gmail.com](mailto:echochris2@gmail.com); [cebong@idrc-uganda.org](mailto:cebong@idrc-uganda.org)

<sup>1</sup> Infectious Diseases Research Collaboration, Kampala, Uganda  
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Reference

1. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, Asua V, Gudo S, Kigozi R, Tibenderana J, Bwanika JB, Bosco A, Rubahika D, Kyabayinze D, Opigo J, Rutazana D, Sebikaari G, Belay K, Niang M, Halsey ES, Moriarty LF, Lucchi NW, Svigel Souza SS, Nsohya SL, Kanya MR, Yeka A. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. *Malar J.* 2021;20:484. <https://doi.org/10.1186/s12936-021-04021-5>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

